Challenges in Diagnosing Intermediate Maple Syrup Urine Disease by Newborn Screening and Functional Validation of Genomic Results Imperative for Reproductive Family Planning

Maple syrup urine disease is caused by a deficiency of branched-chain alpha-ketoacid dehydrogenase, responsible for degradation of leucine, isoleucine, and valine. Biallelic pathogenic variants in BCKDHA, BCKDHB, or DBT genes result in enzyme deficiency. We report the case of a female infant who presented with mild gross motor delay at 4 months, and seizures with hypoglycaemia at 5 months. Newborn screening returned total leucine/isoleucine at the 99.5th centile of the population; however, as second-tier testing reported minimal alloisoleucine, the results were considered inconsistent with MSUD. Plasma amino acid and urine organic acid analyses at 5 months were, however, consistent with a diagnosis of MSUD. A brain MRI showed bilateral symmetrical T2 hyperintense signal abnormalities involving white matter, globus pallidus, thalamus, brainstem, and dentate nuclei with restricted diffusion. A repeat MRI 10 months post-dietary-intervention showed the resolution of these changes and progression in myelination. Her clinical phenotype, including protein tolerance, correlated with intermediate MSUD. Molecular analysis of all three genes identified two variants of uncertain significance, c.434-15_434-4del and c.365A>G (p. Tyr122Cys) in the DBT gene. The rate of leucine decarboxylation in fibroblasts was reduced, but not to the extent observed in classical MSUD patients, supporting an intermediate form of MSUD. Previously reported mRNA splicing studies supported a deleterious effect of the c.434-15_434-4del variant. This functional evidence and confirmation that the variants were in trans, permitted their reclassification as pathogenic and likely pathogenic, respectively, facilitating subsequent prenatal testing. This report highlights the challenges in identifying intermediate MSUD by newborn screening, reinforcing the importance of functional studies to confirm variant pathogenicity in this era of molecular diagnostics.

[1]  I. Knerr,et al.  Maple syrup urine disease: Clinical outcomes, metabolic control, and genotypes in a screened population after four decades of newborn bloodspot screening in the Republic of Ireland , 2020, Journal of inherited metabolic disease.

[2]  P. Blackburn,et al.  Maple syrup urine disease: mechanisms and management , 2017, The application of clinical genetics.

[3]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[4]  J. Christodoulou,et al.  An improved ultra performance liquid chromatography-tandem mass spectrometry method for the determination of alloisoleucine and branched chain amino acids in dried blood samples , 2011, Annals of clinical biochemistry.

[5]  G. Homanics,et al.  Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease , 2008, Brain : a journal of neurology.

[6]  K. Bhattacharya,et al.  Newborn screening may fail to identify intermediate forms of maple syrup urine disease , 2006, Journal of Inherited Metabolic Disease.

[7]  S. Blaser,et al.  Atypical phenotype in a boy with a maple syrup urine disease , 2006, Journal of Inherited Metabolic Disease.

[8]  E. Puffenberger,et al.  Diagnosis and treatment of maple syrup disease: a study of 36 patients. , 2002, Pediatrics.

[9]  U. Wendel,et al.  Whole-Body l-Leucine Oxidation in Patients with Variant Form of Maple Syrup Urine Disease , 2001, Pediatric Research.

[10]  D. Chuang,et al.  Maple syrup urine disease: it has come a long way. , 1998, The Journal of pediatrics.

[11]  D. Chuang,et al.  E2 transacylase-deficient (type II) maple syrup urine disease. Aberrant splicing of E2 mRNA caused by internal intronic deletions and association with thiamine-responsive phenotype. , 1997, The Journal of clinical investigation.

[12]  G. Lynch,et al.  Maple Syrup Urine Disease , 1964, Journal of mental deficiency research.

[13]  C. Dionisi-Vici,et al.  Branched-chain Organic Acidurias /Acidaemias , 2012 .

[14]  D. Millington,et al.  Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. , 1995, Clinical chemistry.